Cassava Sciences, Inc.

NasdaqCM SAVA

Cassava Sciences, Inc. Free Cash Flow Yield on January 14, 2025: -62.17%

Cassava Sciences, Inc. Free Cash Flow Yield is -62.17% on January 14, 2025, a -721.28% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Cassava Sciences, Inc. 52-week high Free Cash Flow Yield is -5.04% on November 21, 2024, which is 91.89% above the current Free Cash Flow Yield.
Cassava Sciences, Inc. 52-week low Free Cash Flow Yield is -70.86% on December 19, 2024, which is -13.97% below the current Free Cash Flow Yield.
Cassava Sciences, Inc. average Free Cash Flow Yield for the last 52 weeks is -15.30%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: SAVA

Cassava Sciences, Inc.

CEO	Mr. Richard Jon Barry
IPO Date	July 14, 2000
Location	United States
Headquarters	7801 North Capital of Texas Highway
Employees	29
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Key trends

Past 5 years